COMPANY

Biolojic Design

Our pipeline of computationally designed programmable antibodies focuses on autoimmune diseases and immuno-oncology. From company website Source · Oct 13, 2026

Keywords: antibodies oncology BD200

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Timeline

Dec 31, 2026 Trial start Phase 1: This Clinical Study is to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of BD200 in Participants With Advanced or Metasta source ↗

Upcoming milestones

Dec 31, 2028 (ESTIMATED) · Phase 1 · This Clinical Study is to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of BD200 in Participants With Advanced or Metastatic Cance · NCT07797907

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07797907	This Clinical Study is to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of BD200 in Participants With Advanced or Metastatic Cancer.	Phase 1	Not yet recruiting	Dec 31, 2026	Dec 31, 2028 (estimated)